Business Wire

Marrakech Investor Day: International Investors are Choosing Marrakech, One of the World’s Dream Destinations

7.4.2022 12:28:00 EEST | Business Wire | Press release

Share

In collaboration with the International Finance Corporation (IFC) and the Swiss State Secretariat for Economic Affairs (SECO), the Marrakech-Safi Regional Center for Investment hosted the inaugural edition of the Marrakech Investor Day, a meaningful event designed to allow hundreds of investors to explore the fantastic advantages and new investment opportunities across Marrakech.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220407005464/en/

Global supply chain disruptions, recent geopolitical changes, and the “Green Production” requirement, coupled with the multiple free trade agreements that provide direct access to more than 1.3 billion consumers, have aptly positioned Marrakech as the sustainable alternative for investors around the world.

Marrakech is a captivating imperial city boasting a sub-tropical mild climate and beautiful landscapes that make it an unmissable tourist destination. Moreover, Morocco provides attractive advantages for investors from all over the world. These advantages include political stability, a geo-strategic location and direct access to Europe and Africa’s markets, an attractive business-friendly environment, a robust, modern infrastructure, and prestigious talents taught in two of Africa’s best universities, all combined with a unique lifestyle and improved quality of life.

Marrakech, a city at the forefront of sustainability

Driven by the unrelenting will of the King of Morocco, with a target to generate 52% of energy from renewable sources by 2030, Marrakech offers investors the opportunity to put a little “green” in their portfolios and decarbonize the world’s industries.

The event was also an opportunity to explore the cultural richness and diversity of Marrakech, which actively encourages and facilitates foreign investments in multiple sectors, such as the agribusiness, tourism, creative industries, renewable energy, logistics, offshoring, and ICT.

These investment opportunities were made possible thanks to multiple reforms and facilitation mechanisms, which offer several incentives to stimulate investment (up to 30% of the total investment amount), improve the business climate and the competitiveness of the private sector.

More than 50 non-double taxation agreements, the absence of restrictions in the percentage of share capital and the free repatriation of funds are also influential factors that enable the region to offer a particularly modern and attractive legal and fiscal environment.

As part of the Marrakech Investor Day’s events, international investors were given a first-hand demonstration of these advantages that promote ease of doing investments in Marrakech and enhance transparency, such as the dematerialization of customs procedures and the personalized support of the Marrakech-Safi Regional Center for Investment.

The event also featured a panel discussion on the data-related investment opportunities, followed by the Marrakech Investor Awards ceremony, designed to celebrate the regions’ key investors.

To relive the event, and learn more about investment opportunities in Marrakech, visit www.marrakechinvest.ma

About:

The Regional Investment Center of Marrakech-Safi is a public institution with a mission is to facilitate, support and promote investments in the Marrakech-Safi region.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hanaa Zouzaf
h.zouzaf@crimarrakech.ma

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye